Hematological Malignancies Drugs Market Size, Share & Trends Analysis Report By Drugs (Monoclonal Antibodies, CAR-T Cell Therapy), By Pipeline Products, By Indication (Leukemia, Lymphoma), By Region, And Segment Forecasts, 2024-2031

Report Id: 1211 Pages: 180 Last Updated: 20 August 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation Of Hematological Malignancies Drugs Market

Global Hematological Malignancies Drugs Market , by Drugs

  • Monoclonal Antibodies
    • Blincyto (Blinatumomab)
    • Besponsa (Inotuzumab Ozogamicin)
    • Lumoxiti (Moxetumomab Pasudotox)
    • Mylotarg (Gemtuzumab Ozogamicin)
    • Opdivo (Nivolumab)
    • AiRuiKa (Camrelizumab)
    • Tyvyt (Sintilimab)
    • Tislelizumab
    • Gazyva (Obinutuzumab)
    • Zynlonta (Loncastuximab Tesirine-lpyl)
    • Darzalex (Daratumumab)
    • Blenrep (Belantamab Mafodotin-blmf)
    • Keytruda (Pembrolizumab)
    • Adcetris (Brentuximab Vedotin)
    • Arzerra (Ofatumumab
  • CAR-T Cell Therapy 
    • Tecartus (Brexucabtagene Autoleucel)
    • Kymriah (Tisagenlecleucel)
    • Yescarta (Axicabtagene Ciloleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel) 

hematological malignancies

Global Hematological Malignancies Drugs Market , by Pipeline Products

  • Monoclonal Antibodies
  • Teclistamab
  • Iomab-B
  • Ublituximab
  • CS1001
  • CAR-T Cell Therapy
  • Ciltacabtagene Autoleucel (JNJ-68284528)

Global Hematological Malignancies Drugs Market , by Indications

  • Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Lymphoma
  • Hodgkin’s Lymphoma
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma

Global Hematological Malignancies Drugs Market , by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North AmericaHematological Malignancies Drugs Market , by Country

  • U.S.
  • Canada

Europe Hematological Malignancies Drugs Market , by Country

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia PacificHematological Malignancies Drugs Market , by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Hematological Malignancies Drugs Market , by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Hematological Malignancies Drugs Market , by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immune-Onc Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Other Prominent Players

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Hematological Malignancies Drugs Market Snapshot

Chapter 4. Global Hematological Malignancies Drugs Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis

5.1. By Drugs, & Market Share, 2023 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drugs:

5.2.1. Monoclonal Antibodies

5.2.1.1. Blincyto (Blinatumomab)

5.2.1.2.  Besponsa (Inotuzumab Ozogamicin)

5.2.1.3.  Lumoxiti (Moxetumomab Pasudotox)

5.2.1.4.  Mylotarg (Gemtuzumab Ozogamicin)

5.2.1.5.  Opdivo (Nivolumab)

5.2.1.6.  AiRuiKa (Camrelizumab)

5.2.1.7.  Tyvyt (Sintilimab)

5.2.1.8.  Tislelizumab

5.2.1.9.  Gazyva (Obinutuzumab)

5.2.1.10.  Zynlonta (Loncastuximab Tesirine-lpyl)

5.2.1.11.  Darzalex (Daratumumab)

5.2.1.12.  Blenrep (Belantamab Mafodotin-blmf)

5.2.1.13.  Keytruda (Pembrolizumab)

5.2.1.14.  Adcetris (Brentuximab Vedotin)

5.2.1.15.  Arzerra (Ofatumumab)

5.2.2. CAR-T Cell Therapy

5.2.2.1. Tecartus (Brexucabtagene Autoleucel)

5.2.2.2.  Kymriah (Tisagenlecleucel)

5.2.2.3.  Yescarta (Axicabtagene Ciloleucel)

5.2.2.4.  Breyanzi (Lisocabtagene Maraleucel)

5.2.2.5.  Abecma (Idecabtagene Vicleucel)

Chapter 6. Market Segmentation 2: By Indications Estimates & Trend Analysis

6.1. By Pipeline Products & Market Share, 2023 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Pipeline Products:

6.2.1. Monoclonal Antibodies

6.2.1.1. Teclistamab

6.2.1.2.  Iomab-B

6.2.1.3.  Ublituximab

6.2.1.4.  CS1001

6.2.2. CAR-T Cell Therapy

6.2.2.1. Ciltacabtagene Autoleucel (JNJ-68284528)

Chapter 7. Market Segmentation 3: By Pipeline Products Estimates & Trend Analysis

7.1. By Indications & Market Share, 2023 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Indications:

7.2.1. Leukemia

7.2.1.1. Acute Lymphoblastic Leukemia

7.2.1.2.  Chronic Lymphoblastic Leukemia

7.2.1.3.  Acute Myeloid Leukemia

7.2.2. Lymphoma

7.2.2.1. Hodgkin’s Lymphoma

7.2.2.2.  Non-Hodgkin’s Lymphoma

7.2.3. Multiple Myeloma

Chapter 8. Hematological Malignancies Drugs Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Drugs, 2024-2031

8.1.2. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Pipeline Products, 2024-2031

8.1.3. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts By Indications, 2024-2031

8.1.4. North America Hematological Malignancies Drugs Market revenue (US$ Million) estimates and forecasts by country, 2024-2031

8.2. Europe

8.2.1. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031

8.2.2. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031

8.2.3. Europe Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031

8.2.4. Europe Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031

8.3.2. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031

8.3.3. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031

8.3.4. Asia Pacific Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031

8.4. Latin America

8.4.1. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031

8.4.2. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031

8.4.3. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031

8.4.4. Latin America Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Drugs, 2024-2031

8.5.2. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Pipeline Products, 2024-2031

8.5.3. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) By Indications, 2024-2031

8.5.4. Middle East & Africa Hematological Malignancies Drugs Market revenue (US$ Million) by country, 2024-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. AbbVie Inc.

9.2.2. Amgen Inc.

9.2.3. Bristol-Myers Squibb Company

9.2.4. F. Hoffmann-La Roche Ltd.

9.2.5. Gilead Sciences, Inc.

9.2.6. GlaxoSmithKline plc

9.2.7. Immune-Onc Therapeutics, Inc.

9.2.8. Johnson & Johnson Services, Inc.

9.2.9. Merck & Co., Inc.

9.2.10. Novartis International AG

9.2.11. Pfizer Inc.

9.2.12. Sanofi S.A.

9.2.13. Takeda Pharmaceutical Company Limited

9.2.14. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
7007
Security Code field cannot be blank!

Frequently Asked Questions

Few key players operating in theHematological Malignancies Drugs Market are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Roche

The Hematological Malignancies Drugs Market Size is valued at XX Billion in 2023 and is predicted to reach XX Billion by the year 2031.

The Hematological Malignancies Drugs Market is expected to grow at a 14.20% CAGR during the forecast period for 2024-2031.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying